Bank of Montreal’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Bank of Montreal’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,500	Closed	-$3K	–	5098
2019 Q4	$3K	Sell	5,500 -7,400	-57%	-$17.9K	﹤0.01%	4763
2019 Q3	$49K	Buy	12,900 +7,397	+134%	+$26.6K	﹤0.01%	3637
2019 Q2	$37K	Buy	5,503 +3,945	+253%	+$15K	﹤0.01%	3837
2019 Q1	$6K	Sell	1,558 -95	-6%	-$516	﹤0.01%	4016
2018 Q4	$6K	Buy	1,653 +51	+3%	+$652	﹤0.01%	4066
2018 Q3	$32K	Buy	1,602 +20	+1%	+$506	﹤0.01%	3563
2018 Q2	$50K	Sell	1,582 -6	-0.4%	-$216	﹤0.01%	3408
2018 Q1	$58K	Buy	1,588 +34	+2%	+$2.23K	﹤0.01%	3181
2017 Q4	$123K	Buy	+1,554	New	+$115K	﹤0.01%	2921

Bank of Montreal's MLNT Position: Q1 2020 in Review

Bank of Montreal sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 5,500 shares — an estimated $3K sold.

Bank of Montreal first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $123K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Bank of Montreal reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Bank of Montreal sold 5,500 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $3K.
Bank of Montreal first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Bank of Montreal's Melinta Therapeutics, Inc. Common Stock position peaked at $123K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Bank of Montreal's 13F filing for Q1 2020, filed 13 May 2020.